Clinician reference tool — not medical advice. This is a clinical decision-aid intended for healthcare professionals: it gives deterministic suggestions to think with, not a diagnosis or a prescription. If you’re a patient, you’re welcome to look around — but please review anything here with your own doctor; it isn’t a substitute for personalized medical care.

Evidence: Hypertension Canada 2025 · sources last checked 2026-07-07

Reference tool — not medical advice. Thresholds, targets, and first-line agents differ by guideline body and change over time — switch the lens to compare. Clinician judgement, dosing/monitoring, contraindications, and live coverage always required. Runs entirely in your browser — no data is collected.

Hypertension selector

Choose the guideline lens, enter the BP and the patient’s risk factors — get the classification, treatment target, whether to start drugs, and a comorbidity-driven first-line agent recommendation, with each guideline’s year shown.

Guideline lens

Systolic BP (mmHg)choose one

Diastolic BP (mmHg)choose one

Measurement methodchoose one

Out-of-office confirmation is preferred to rule out white-coat / masked hypertension

Agechoose one

Demographics

Comorbidities (compelling indications)

Treatment context

Contraindications & cautions

Treatment target

SBP < 130 mmHg (unified)

Notes

  • • Hypertension Canada 2025: unified SBP <130 target; three preferred first-line classes (ACEi/ARB, thiazide-like, long-acting DHP-CCB); upfront low-dose single-pill combination preferred.

Suggested drug classesPer Hypertension Canada 2025.

Enter a BP and any risk factors to begin.

Switch the guideline lens to see the 130/80-vs-140/90 threshold split, ESC’s “elevated BP” band, and NICE’s A/C/D algorithm change the output.

Guidelines

References

  1. [1]Hypertension Canada. Guideline for the Diagnosis and Treatment of Hypertension in Adults in Primary Care. CMAJ 2025;197:E549 (supersedes the 2020 Comprehensive Guidelines). link
  2. [2]NICE NG136 — Hypertension in adults: diagnosis and management (A/C/D algorithm; step-4 spironolactone K⁺ gate). Updated 2026. link
  3. [3]2025 ACC/AHA Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (replaces 2017; PREVENT risk equation; race-neutral drug selection). link
  4. [4]2024 ESC Guidelines for the management of elevated blood pressure and hypertension (new 'elevated BP' 120–139/70–89 band; 120–129 target range). link
  5. [5]2023 ESH Guidelines for the management of arterial hypertension (retains 140/90 diagnostic threshold; separate from ESC). link
  6. [6]PROGRESS Collaborative Group. Perindopril-based blood-pressure-lowering (± indapamide) after stroke/TIA. Lancet 2001;358:1033. link
  7. [7]Williams B, et al. PATHWAY-2: Spironolactone for resistant hypertension. Lancet 2015;386:2059. link
  8. [8]SOGC Guideline No. 426: Hypertensive Disorders of Pregnancy. J Obstet Gynaecol Can 2022. / Hypertension Canada 2018 pregnancy chapter. link
  9. [9]Tita AT, et al. CHAP: Treatment for Mild Chronic Hypertension during Pregnancy (target <140/90). NEJM 2022;386:1781. link
  10. [10]ISH 2020 Global Hypertension Practice Guidelines (Unger P, et al. J Hypertens 2020;38:982). link
  11. [11]Ontario Drug Benefit (ODB) e-Formulary — standard antihypertensive classes are broadly covered; confirm live before counselling on coverage. link